A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Phase 1
75
about 2.6 years
18+
10 sites in CA, CT, FL +6
About this study
This trial is testing a new treatment called XB628 for people with advanced solid tumors. It's a phase 1 trial, meaning it's the first time this treatment is being tested in humans. The goal is to determine the best dose of XB628 and how well it works.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive XB628
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants with Dose Limiting Toxicities (DLTs), Number of Participants with Serious Adverse Events (SAEs), Treatment-emergent Adverse Events (TEAEs), and Adverse Events (AEs) Leading to Dose Withholding, Treatment Discontinuation, or Death
Secondary: Apparent Clearance (CL/F) of XB628, Area Under the Concentration-time Curve (AUC) of XB628, Duration of Response (DOR), Elimination Half-life (T1/2) of XB628, Maximum Plasma Concentration (Cmax) of XB628, Objective Response Rate (ORR), Time to Maximum Concentration (Tmax) of XB628
Oncology